Insmed (INSM) is down after the company’s recent clinical update that it will discontinue development of brensocatib (Brinsupri) in hidradenitis suppurativa following a Phase 2b trial failure, a headline that continues to pressure biotech sentiment and positioning. The move reflects ongoing post-update selling rather than a single new intraday catalyst, with investors repricing the probability of label expansion and future pipeline optionality. (investing.com)

In the days surrounding the program discontinuation, multiple firms adjusted their views, including price-target reductions while generally maintaining positive ratings—moves that can still weigh on the stock by signaling more limited near-term upside. Recent examples include Mizuho lowering its target while keeping an Outperform rating and H.C. Wainwright cutting its target while maintaining a Buy rating. (investing.com)

With an HS expansion effort now shelved, investors are likely to focus on execution in Insmed’s commercial franchise and the next set of pipeline catalysts, plus any commentary on capital allocation and operating spend. The next confirmed earnings date shown by market trackers is April 30, 2026, which may become the next focal point for guidance framing and updates on launch momentum in the core respiratory portfolio. (tipranks.com)